Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Liu XL, Xu YC, Wang YX, Chen Y, Wang BB, Wang Y, Chen YH, Tan C, Hu LD, Ma QY, Zhang YC, Sun YM, Gao YL, Yang CH, Ding J, Meng LH.
Liu XL, et al. Among authors: meng lh.
Cancer Lett. 2018 Oct 1;433:273-282. doi: 10.1016/j.canlet.2018.07.011. Epub 2018 Jul 9.
Cancer Lett. 2018.
PMID: 30003928